EARLY DYNAMICS OF THE SYSTEMIC INFLAMMATION RESPONSE INDEX PREDICT OUTCOMES IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB (SIE 2026) - Oct 6, 2026 - Abstract #DP204; Pres time: Sep 22, 2026; 06:30 PM - 07:30 PM; Location: AREA POSTER; "Conversely, 6-month SIRI dynamics, with the failure to reduce inflammation and/or high inflammatory state, may help to identify patients with suboptimal drug response, significantly poorer survival and need to switch to a second line treatment. These data may integrate the predictive strength of RR6 prognostic score."
Biomarker • Clinical • Immunology • Inflammation • Myelofibrosis • Systemic Inflammatory Response Syndrome
|
|
A. Laganà; E. Scalzulli; I. Carmosino; M. L. Bisegna; M. Gherardini; D. Kasmi; A. L. Faccini; C. Andriola; M. Martelli; M. Breccia
|